Human cytomegalovirus (CMV) DNA in plasma reflects quantity of CMV DNA present in leukocytes.
A quantitative DNA amplification assay for human cytomegalovirus (CMV) DNA has been used to evaluate the relationship between quantities of CMV DNA in plasma and those in infected leukocytes (WBC) from human immunodeficiency virus-infected patients. The target sequence for DNA amplification was a region of the immediate-early 1 gene of CMV. The quantitation assay uses an internal control that is coamplified with each patient sample DNA and contains a sequence for detection by colorimetric hybridization with the same bases, but in different order than in the CMV immediate-early 1 region used for hybridization of amplified patient sample DNA. Results showed that patients with CMV disease had more CMV DNA in both WBC and plasma than those without disease. However, in this study, copy numbers of CMV DNA in WBC were higher than those in plasma. The gB and gH variants were the same in plasma and WBC.
Zipeto
D
D
Division of Infectious Diseases, Stanford University School of Medicine, California 94305, USA.
Morris
S
S
Hong
C
C
Dowling
A
A
Wolitz
R
R
Merigan
T C
TC
Rasmussen
L
L
D001483:Base Sequence; D003586:Cytomegalovirus Infections / Q000097:blood* / Q000209:etiology / Q000473:pathology; D004279:DNA, Viral / Q000097:blood / Q000302:isolation & purification*; D005838:Genotype; D015658:HIV Infections / Q000150:complications*; D006801:Humans; D007962:Leukocytes / Q000821:virology*; D008969:Molecular Sequence Data; D016133:Polymerase Chain Reaction; D012661:Semen / Q000166:cytology / Q000821:virology
D004279:DNA, Viral